Study guide
4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
PEBC Pharmacist Qualifying Examination Part I MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation
1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice
2 Chapter 2: Ethics, Scope of Practice & Safety Culture
2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement
3 Chapter 3: Pharmaceutical Calculations & Posology
3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
4 Chapter 4: Compounding, Dispensing & Product Integrity
4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
5 Chapter 5: Clinical Pharmacology & Pharmacokinetics
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
6 Chapter 6: Evidence-Based Medicine & Literature Appraisal
6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD
7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)
8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation
8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)
9 Chapter 9: Endocrine & Metabolic Disorders
9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)
10 Chapter 10: Respiratory & Gastrointestinal Disorders
10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship
11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections
12 Chapter 12: Central Nervous System & Mental Health
12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
13 Chapter 13: Special Populations, Pain Management & Substance Use
13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy
14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care
14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care
15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health
15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder
16 Chapter 16: Immunization & Health Promotion
16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
17 Chapter 17: Patient Care Process, Communication & Stewardship
17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship
4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
Key Takeaways Explain This Topic AI
Generic substitution is governed by provincial interchangeability lists, a prescriber's no-substitution direction must be honoured, and biosimilars are not interchanged at the counter.
Claim rejections and drug utilization review alerts must be investigated and documented; changing the days' supply or quantity to get around a payer edit is fraud.
Moisture-sensitive products such as dabigatran stay in the original package, and returned medications are never re-dispensed.
Confirm identity at release with two patient-provided identifiers, such as address and date of birth.
A controlled-substance count discrepancy is first checked against records such as balances owing; an unexplained loss is reported to Health Canada within 10 days.
Last updated: October 2026
Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
About 20% of Part I items come from the Distribution domain (competencies 1.6 to 1.10). Many of these are not about compounding or calculations. They test the daily operational decisions that keep dispensing safe and lawful: which product may be substituted, how a claim is adjudicated, what goes into a compliance pack, how a prescription is released, and how inventory, including controlled substances, is reconciled. This section brings those operations together.
1. Interchangeability and Generic Substitution
Health Canada authorizes a generic through an Abbreviated New Drug Submission that shows bioequivalence to the Canadian Reference Product (section 1.1). Whether a pharmacist may substitute one product for another, however, is a provincial matter:
Interchangeability lists: each province publishes a formulary or list of interchangeable products (for example, Ontario's Formulary/Comparative Drug Index). Substitution is allowed only between products listed as interchangeable.
Prescriber "no substitution": when the prescriber writes "no substitution" (or the provincial equivalent), the pharmacist dispenses the brand prescribed. Public plans often reimburse only the lowest-cost interchangeable product, so the patient may pay the difference.
Patient choice: a patient may decline a generic and pay the difference where plan rules allow.
Narrow-therapeutic-index drugs: substitution is lawful between listed interchangeable products, but switching manufacturers back and forth for drugs such as levothyroxine, warfarin, antiepileptics or cyclosporine warrants monitoring (TSH, INR, levels) and counselling.
Biosimilars are not generics. They are not automatically interchangeable at the pharmacy counter. Switching happens through provincial biosimilar policies or a new prescription (section 17.3).
2. Third-Party Adjudication and Drug Utilization Review
Most Canadian prescriptions are adjudicated online in real time to a payer: a provincial public plan, the federal Non-Insured Health Benefits (NIHB) program for eligible First Nations and Inuit clients, Veterans Affairs, or a private insurer. Key points:
Claim rejections carry codes such as "refill too soon", "drug not a benefit", "special authorization required" or "maximum quantity exceeded". A rejection is a prompt to investigate, never a reason to falsify days' supply or quantities. Billing a false days' supply to get around a refill-too-soon edit is fraud.
Drug utilization review (DUR) alerts from provincial networks (for example, drug interaction, duplicate therapy, or multiple-prescriber flags) must be assessed and documented. An intervention code is entered only after the pharmacist has actually resolved the issue.
Coordination of benefits: when a patient has two plans, the primary payer is billed first and the balance is submitted to the secondary plan.
Special or exception authorization (for example, for biologics) needs prescriber documentation. The pharmacist can help by identifying criteria and coverage alternatives.
3. Prescription Transfers, Part-Fills and Balances Owing
Non-controlled prescriptions are transferred under provincial rules. The receiving pharmacy records the transferring pharmacy, the original prescription details, remaining refills, and the dates.
Controlled substances may be transferred by a pharmacist or a pharmacy technician within 2 years of the original receipt, with the written prescription or verbal-prescription record. The transfer is documented by both sides (CSR s. 102 and s. 119).
Part-fills and "owes": when stock is short, the pharmacy dispenses part of the quantity and records a balance owing . During a controlled-substance count, balances owing are tablets that are legitimately still on the shelf . They must be accounted for before a shortage is called a loss.
4. Compliance Packaging (Blister and Pouch Packs)
Multi-drug compliance packaging improves adherence for patients with complex regimens or cognitive impairment, but it is a form of repackaging:
Consideration Practice point
Stability Moisture-sensitive or light-sensitive products may not tolerate repackaging. Dabigatran capsules must stay in the original package; nitroglycerin SL tablets, effervescent tablets and many orally disintegrating tablets are also unsuitable.
Labelling Each pack lists every drug with strength, directions and a description (colour, shape, imprint), plus the prescriber, date and pharmacy.
Hazardous drugs Antineoplastics and other hazardous drugs need extra precautions (gloves, dedicated equipment, or separate packaging).
"As needed" and variable doses PRN medications and tapering or alternating doses (for example, warfarin regimens) are usually supplied separately, or the regimen is restructured into whole tablets.
Changes mid-cycle A dose change means removing and rebuilding the affected packs. Never "add" a tablet to a sealed cell.
5. Releasing the Prescription
The final step is where wrong-patient errors are caught or missed:
Confirm identity with two identifiers , for example the patient's address and date of birth . Do not simply ask "Are you Mr. Smith?", because anxious or hard-of-hearing patients often say yes. PEBC's sample items use address plus date of birth.
Check the bag against the profile: right patient, right drugs, right number of items.
Counsel on new prescriptions and changes, and ask open-ended questions for refills ("How are you taking it?").
Controlled substances are released by the pharmacist (CSR s. 98). Pickup by an agent and delivery must follow provincial policy, and any delivery must be secure and trackable (CSR s. 107).
6. Inventory Management, Returns and Disposal
Rotation: first-expiry, first-out. Check expiry dates on a schedule, and quarantine expired stock until it is returned or destroyed.
Cold chain: refrigerated products are stored at 2 to 8°C with continuous or twice-daily temperature logging. Excursions are quarantined and evaluated with the manufacturer (section 4.3).
Recalls: quarantine affected lots, identify patients, and document the response (section 1.1).
Returned medications are never re-dispensed once they have left the pharmacy, because storage conditions and tampering cannot be verified. Patient returns go to the disposal stream. Industry take-back programs, such as those run by the Health Products Stewardship Association in several provinces, collect unused medications from community pharmacies.
Returned controlled substances go into a secure, marked collection container. They are then destroyed in the pharmacy with a witness and joint declaration, or sent to a licensed dealer specialized in destruction (CSR s. 104 and s. 110).
7. Controlled-Substance Reconciliation
Regular counts compare the expected inventory (opening balance + receipts − dispensed − destroyed − transferred) with the physical count. When they differ:
Recount and confirm the expected figure.
Look for paper explanations first: unrecorded receipts, prescriptions entered in the wrong strength or product, balances owing , returns to supplier, and destruction not yet recorded.
Review high-risk patterns: voided or reversed transactions, unusual part-fills, and access logs.
If the shortage remains unexplained, treat it as a loss. Report it in writing to Health Canada within 10 days (CSR s. 109), notify police if theft is suspected, and inform the provincial college if its standards require it.
Never adjust the count to match the expected figure without finding the cause.
Tip
PEBC sample items reward the methodical sequence: after a count discrepancy, the next step is to check for outstanding balances owing and other record explanations. It is not to adjust the inventory, and not to report immediately before the records have been checked.